What is BioConsortia?
BioConsortia is at the forefront of agricultural biotechnology, leveraging a proprietary methodology to identify and develop beneficial microbial consortia for substantial crop enhancement. The company's pipeline targets critical areas in agriculture, including optimizing nutrient utilization (N, P, K, S fertilizers), promoting plant growth for increased yield and accelerated development, and enhancing desirable crop traits such as abiotic stress tolerance, biotic resistance, and improved metabolite expression. BioConsortia aims to collaborate with leading crop protection, seed, and plant breeding companies to integrate its advanced microbial solutions into sustainable agricultural practices.
How much funding has BioConsortia raised?
BioConsortia has raised a total of $63.3M across 6 funding rounds:
Series B
$15M
Series C
$8M
Series D
$10M
Debt
$350K
Other Financing Round
$15M
Other Financing Round
$15M
Series B (2014): $15M with participation from Khosla Ventures Acquisition and Otter Capital LLC
Series C (2016): $8M led by Otter Capital LLC and Khosla Ventures Acquisition
Series D (2018): $10M supported by Khosla Ventures Acquisition and Otter Capital
Debt (2020): $350K featuring PPP
Other Financing Round (2024): $15M backed by Otter Capital
Other Financing Round (2025): $15M with participation from Otter Capital
Key Investors in BioConsortia
Khosla Ventures Acquisition
Khosla Ventures is a venture capital firm founded in 2004, known for providing venture assistance and strategic advice to entrepreneurs focused on breakthrough technologies across various sectors including agriculture and sustainable energy.
Otter Capital LLC
Otter Capital LLC is an investment firm with a strong background in agriculture and food production companies, having previously invested in AgraQuest and BioConsortia, and is led by John Pasquesi, a former Managing Director at Hellman & Friedman.
PPP
Public-Private Partnership
What's next for BioConsortia?
With the recent influx of major strategic investment, BioConsortia is poised for an accelerated growth phase. The company's focus will likely be on scaling its research and development efforts, advancing its pipeline products towards commercialization, and forging strategic partnerships. This capital infusion signals strong investor confidence in BioConsortia's innovative approach to sustainable agriculture and its potential to disrupt traditional farming methods. The company's trajectory suggests a move towards broader market adoption and further expansion of its product offerings in the agricultural biotechnology sector.
See full BioConsortia company page
